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The role of cyclodextrin’s (CD) in drug delivery has advanced in recent years and this may be attributed to its biocompatibility and well established synthesis. Chemical modification of CDs has shown to 
extend the physicochemical properties and the host capacity for a variety of drugs. β-CD has been widely used in the early stages of pharmaceutical applications because of its ready availability and its 
cavity size suitability for a wide range of drugs. Chemical modification of β-CD has proven to enhance aqueous solubilisation, microbiological stability and reduced toxicity in previous studies.1 Folate 
Receptors are over-expressed in several human cancers including ovarian, breast and renal carcinomas. This property has been utilised to develop tumour-selective anti-neoplastic drugs.  Folate has been 
bound to chemotherapeutic drugs and since tumour cells have a huge appetite for folate, their folate receptors ‘pull’ the drug-folate conjugate towards the tumour site.  However the direct conjugation of 
folate to the bioactive drug can lead to loss of targeting or alter the function of the conjugate. Folate-cyclodextrin bioconjugates have been prepared with polyethylene glycol (PEG) linkers; however this 
conjugate partially prevents drug degradation.2,3 This study describes the synthesis and characterisation (UV-Vis, Emission, IR, Raman, NMR, MALDI-MS and ESI-MS) of a novel folate-cyclodextrin 
bioconjugate (CDEn-FA). As mentioned previously it was found that direct conjugation of folate to the bioactive molecules led to loss of targeting or an alteration of the function of the conjugate and most of 
the conjugates to date cannot be further modified to improve targeting or anti-tumour activity.4-8 Preliminary biological evaluation of the tumour targeting device will be discussed. 
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Cyclodextrins easily form inclusion compounds with a wide range of 
inorganic and organic molecules. One Application is in drug delivery 
by the formation of inclusion complexes, e.g., in combination with 
different drugs, it is possible to control the release rate of drugs.9 
 
 
INTRODUCTION  
 
Figure 2. Structure of Folic Acid; Mechanism of targeting for a 
carrier-Folate.15 
 
Targeted drug delivery systems are molecular tools which without 
undesired interaction at other sites target a specific drug 
receptor. Any adverse toxicity would be avoided and only the 
desired therapeutic gain would be produced.12 Folic acid (FA) 
has been chosen as a cancer targeting agent and it is recognised 
by the tumour cells by folate receptors (FR).13 Conjugates of 
folate are extremely potent specific agents that target tumour 
cells expressing the high-affinity folate receptor.14 
The aim of this work is to develop a new nano-vehicle as a drug 
delivery systems for cancer pathology applications. 
 
SYNTETIC STRATEGY 
Figure 1. Formation of  inclusion CD complex with a guest molecule.10,11  
 
ABSTRACT 
SPECTROSCOPIC CHARACTERISATION  
 
  
 
DISCUSSION OF RESULTS 
 
REFERENCES 
The microscopy analysis does not show cytotoxicity of the CDEn-Fa material. 
Figure 4. Fluorescence microscopy analysis (merging images from rhodamine 
and DAPI filter) of HeLa cells. The cells were treated with CDEN-FA at 2:10 
(A), 3:10 (B) molar ratio (CDEn-FA, 100 µM), Folic Acid (as control) at 3:10 (C) 
were stained with HOECHST 33342 dye in phosphate buffer solution (10mM, 
pH 7.4).  
  
 
 BIOLOGICAL EVALUTATION 
 
A B C 
 1H-NMR was assigned by COSY NMR. The 1H-NMR shows three groups of signals (three for each aromatic  proton) 
which are representative of the folic acid portion in three different configurations as shown in Figure 5. By ROESY 
NMR it was possible to assess the phenyl group of the folate moieties which can interact with the cavity of the CD. 
ESI-MS  confirms the formation of the CD conjugated product as shown in Figure 7. UV-VIS absorption analysis of 
CDEn, FA and product CDEn-FA show different  absorption spectra as shown in Figure 6. The HPLC-PDA has 
evaluated the stability and purity of the product. The material presents traces of CDEN and FA not reacted. Preparative 
HPLC experiments are in progress to optimize the purification. During preliminary biological testing, HeLa cells were 
not affected when they were treated with CDEn-FA. These initial biological evaluations allows for further 
experimentation on  cell systems to develop a drug target vehicle.  
   CONCLUSION 
In summary CDEn-FA was synthesized with an attempt to eliminate the polydispersity of the modified CD.2,3 This fact is 
vital in the design and characterisation (thermodynamic properties, photophysics, etc..) of new multifunctional  host-
guest systems having different sites of complexation. By designing a molecular  system with a  controlled  number of 
binding sites ( i.e. targeting moiety, CD cavity,  metal coordination environment) it will be  possible to modulate the 
properties of recognition towards receptor proteins. Such versatility of the CDEn-FA can be exploited  in the 
intracellular delivery of photosensitisers (Photodynamic Therapy of Tumours, PDT)  organic and inorganic drugs in  
conventional anticancer therapy,  metal nanoparticles (Photothermic Therapy of Tumours, PTT).  
The conjugate is fully studied by HPLC-PDA, NMR, MS, UV-VIS, IR and Raman  spectroscopy. 
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Figure 3. Schematic representation of the synthetic route to the formation of CDEn-FA. 
Figure 5. 1H and ROESY NMR in XX solvent of CDEn-FA. 
Figure 6.  Absorption spectra of CDEn, FA and CDEn-FA in 
XXX solvent. 
Figure 7.  ESI-MS of CDEn-FA . 
